Pediatric
Pediatric MDS - Session from the 2025 San Francisco Bay Area Patient and Family Conference
Pediatric PNH - from the 2025 San Francisco Bay Area Patient and Family Conference
Pediatric Aplastic Anemia - 2025 San Francisco Patient and Family Conference
Aplastic Anemia Virtual Support Group - 2026 January
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious co
Kris Michael Mahadeo, MD MPH
Melissa A. McNuall, MD
Russell E. Ware, MD, PhD
Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience
Background: Hematopoietic cell transplantation (HCT) remains the only curative therapy for pediatric myelodysplastic syndrome (MDS) in all but rare cases. While HCT outcomes for pediatric MDS are similar across the largest registry and single-center trials, factors identified as contributing to inferior outcomes vary from study to study. We performed an analysis to provide more clarity on the prognostic implications of disease characteristics, including blast burden and cytogenetic abnormalities, in the current era.
